New insights into biology of Chronic Myeloid Leukemia: Implications in therapy

Current Cancer Drug Targets

Volumn 13, Issue 7, 2013, Pages 711-723

  Cea, Michele ^a,b   Cagnetta, Antonia ^a,b   Nencioni, Alessio ^b   Gobbi, Marco ^b   Patrone, Franco ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Autophagy; BCR ABL; Chronic myeloid leukemia; Genomic instability; Intracellular signaling; Leukemia stem cell

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; BMI1 PROTEIN; BOSUTINIB; CCAAT ENHANCER BINDING PROTEIN ALPHA; DASATINIB; FORKHEAD TRANSCRIPTION FACTOR; FRIZZLED PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MICRORNA; MICRORNA 328; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PONATINIB; PROTEIN KINASE B; RAS PROTEIN; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; SOS PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; BLAST CELL CRISIS; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLONY FORMING UNIT GM; DNA DAMAGE; DNA REPAIR; GENE EXPRESSION; GENOMIC INSTABILITY; HUMAN; INTRACELLULAR SIGNALING; LEUKEMOGENESIS; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84888033830     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990085     Document Type: Article

References (146)

1. Goldman, J. M.; Melo, J. V. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N. Engl. J. Med. 2003, 349, 1451-1464.
2. Black, R. J.; Bray, F.; Ferlay, J.; Parkin, D. M. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur. J. Cancer 1997, 33, 1075-1107.
3. Perrotti, D.; Jamieson, C.; Goldman, J.; Skorski, T. Chronic myeloid leukemia: mechanisms of blastic transformation. J. Clin. Invest. 2010, 120, 2254-2264.
4. Quintas-Cardama, A.; Cortes, J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-1630.
5. Faderl, S.; Talpaz, M.; Estrov, Z.; Kantarjian, H. M. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 1999, 131, 207-219.
6. Konopka, J. B.; Watanabe, S. M.; Witte, O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984, 37, 1035-1042.
7. Daley, G. Q.; Van Etten, R. A.; Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990, 247, 824-830.
8. Greuber, E. K.; Smith-Pearson, P.; Wang, J.; Pendergast, A. M. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 2013, 13, 559-557.
9. Bruns, I.; Czibere, A.; Fischer, J. C.; Roels, F.; Cadeddu, R. P.; Buest, S.; Bruennert, D.; Huenerlituerkoglu, A. N.; Stoecklein, N. H.; Singh, R.; Zerbini, L. F.; Jager, M.; Kobbe, G.; Gattermann, N.; Kronenwett, R.; Brors, B.; Haas, R. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009, 23, 892-899.
10. Daley, G. Q.; Baltimore, D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 9312-9316.
11. Melo, J. V.; Deininger, M. W. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol. Oncol. Clin. North Am. 2004, 18, 545-568, vii-viii.
12. Kurzrock, R.; Gutterman, J. U.; Talpaz, M. The molecular genetics of Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 1988, 319, 990-998.
13. Faderl, S.; Talpaz, M.; Estrov, Z.; O'Brien, S.; Kurzrock, R.; Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med. 1999, 341, 164-172.
14. Pane, F.; Frigeri, F.; Sindona, M.; Luciano, L.; Ferrara, F.; Cimino, R.; Meloni, G.; Saglio, G.; Salvatore, F.; Rotoli, B. Neutrophilicchronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996, 88, 2410-2414.
15. Li, S.; Ilaria, R. L., Jr.; Million, R. P.; Daley, G. Q.; Van Etten, R. A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J. Exp. Med. 1999, 189, 1399-1412.
16. O'Brien, S. G.; Guilhot, F.; Larson, R. A.; Gathmann, I.; Baccarani, M.; Cervantes, F.; Cornelissen, J. J.; Fischer, T.; Hochhaus, A.; Hughes, T.; Lechner, K.; Nielsen, J. L.; Rousselot, P.; Reiffers, J.; Saglio, G.; Shepherd, J.; Simonsson, B.; Gratwohl, A.; Goldman, J. M.; Kantarjian, H.; Taylor, K.; Verhoef, G.; Bolton, A. E.; Capdeville, R.; Druker, B. J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 2003, 348, 994-1004.
17. Saglio, G.; Kim, D. W.; Issaragrisil, S.; Le Coutre, P.; Etienne, G.; Lobo, C.; Pasquini, R.; Clark, R. E.; Hochhaus, A.; Hughes, T. P.; Gallagher, N.; Hoenekopp, A.; Dong, M.; Haque, A.; Larson, R. A.; Kantarjian, H. M. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Eng. J. Med. 2010, 362, 2251-2259.
18. Kantarjian, H.; Shah, N. P.; Hochhaus, A.; Cortes, J.; Shah, S.; Ayala, M.; Moiraghi, B.; Shen, Z.; Mayer, J.; Pasquini, R.; Nakamae, H.; Huguet, F.; Boque, C.; Chuah, C.; Bleickardt, E.; Bradley-Garelik, M. B.; Zhu, C.; Szatrowski, T.; Shapiro, D.; Baccarani, M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Eng. J. Med. 2010, 362, 2260-2270.
19. Ito, T.; Zimdahl, B.; Reya, T. aSIRTing control over cancer stem cells. Cancer Cell 2012, 21, 140-142.
20. Peggs, K.; Mackinnon, S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N. Eng. J. Med. 2003, 348, 1048-1050.
21. Gratwohl, A.; Brand, R.; Apperley, J.; Crawley, C.; Ruutu, T.; Corradini, P.; Carreras, E.; Devergie, A.; Guglielmi, C.; Kolb, H. J.; Niederwieser, D. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006, 91, 513-521.
22. Talpaz, M.; Silver, R. T.; Druker, B. J.; Goldman, J. M.; Gambacorti-Passerini, C.; Guilhot, F.; Schiffer, C. A.; Fischer, T.; Deininger, M. W.; Lennard, A. L.; Hochhaus, A.; Ottmann, O. G.; Gratwohl, A.; Baccarani, M.; Stone, R.; Tura, S.; Mahon, F. X.; Fernandes-Reese, S.; Gathmann, I.; Capdeville, R.; Kantarjian, H. M.; Sawyers, C. L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002, 99, 1928-1937.
23. Sawyers, C. L.; Hochhaus, A.; Feldman, E.; Goldman, J. M.; Miller, C. B.; Ottmann, O. G.; Schiffer, C. A.; Talpaz, M.; Guilhot, F.; Deininger, M. W.; Fischer, T.; O'Brien, S. G.; Stone, R. M.; Gambacorti-Passerini, C. B.; Russell, N. H.; Reiffers, J. J.; Shea, T. C.; Chapuis, B.; Coutre, S.; Tura, S.; Morra, E.; Larson, R. A.; Saven, A.; Peschel, C.; Gratwohl, A.; Mandelli, F.; Ben-Am, M.; Gathmann, I.; Capdeville, R.; Paquette, R. L.; Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002, 99, 3530-3539.
24. Apperley, J. F. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8, 1116-1128.
25. Apperley, J. F. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8, 1018-1029.
26. Hochhaus, A.; Kreil, S.; Corbin, A. S.; La Rosee, P.; Muller, M. C.; Lahaye, T.; Hanfstein, B.; Schoch, C.; Cross, N. C.; Berger, U.; Gschaidmeier, H.; Druker, B. J.; Hehlmann, R. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002, 16, 2190-2196.
27. Jabbour, E.; Kantarjian, H.; Jones, D.; Talpaz, M.; Bekele, N.; O'Brien, S.; Zhou, X.; Luthra, R.; Garcia-Manero, G.; Giles, F.; Rios, M. B.; Verstovsek, S.; Cortes, J. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767-1773.
28. Sen, R.; Natarajan, K.; Bhullar, J.; Shukla, S.; Fang, H. B.; Cai, L.; Chen, Z. S.; Ambudkar, S. V.; Baer, M. R. The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDRassociated ATP-binding cassette transporter ABCG2. Mol. Cancer Therap. 2012, 11, 2033-2044.
29. Cortes, J. E.; Kim, D. W.; Kantarjian, H. M.; Brummendorf, T. H.; Dyagil, I.; Griskevicus, L.; Malhotra, H.; Powell, C.; Gogat, K.; Countouriotis, A. M.; Gambacorti-Passerini, C. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: Results from the BELA trial. J. Clin. Oncol. 2012, 30, 3486-3492.
30. Thomas, E. K.; Cancelas, J. A.; Chae, H. D.; Cox, A. D.; Keller, P. J.; Perrotti, D.; Neviani, P.; Druker, B. J.; Setchell, K. D.; Zheng, Y.; Harris, C. E.; Williams, D. A. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABLinduced myeloproliferative disease. Cancer Cell 2007, 12, 467-478.
31. Sengupta, A.; Arnett, J.; Dunn, S.; Williams, D. A.; Cancelas, J. A. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 2010, 116, 81-84.
32. Chen, Y.; Peng, C.; Sullivan, C.; Li, D.; Li, S. Critical molecular pathways in cancer stem cells of chronic myeloid leukemia. Leukemia 2010, 24, 1545-1554.
33. Jagani, Z.; Dorsch, M.; Warmuth, M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010, 9, 3449-3456.
34. Gregory, M. A.; Phang, T. L.; Neviani, P.; Alvarez-Calderon, F.; Eide, C. A.; O'Hare, T.; Zaberezhnyy, V.; Williams, R. T.; Druker, B. J.; Perrotti, D.; Degregori, J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell 2010, 18, 74-87.
35. Naka, K.; Hoshii, T.; Muraguchi, T.; Tadokoro, Y.; Ooshio, T.; Kondo, Y.; Nakao, S.; Motoyama, N.; Hirao, A. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463, 676-680.
36. Kelliher, M. A.; McLaughlin, J.; Witte, O. N.; Rosenberg, N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 6649-6653.
37. Cilloni, D.; Saglio, G. Molecular pathways: BCR-ABL. Clin. Cancer Res. 2012, 18, 930-937.
38. Deininger, M. W.; Goldman, J. M.; Melo, J. V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96, 3343-3356.
39. Cortez, D.; Kadlec, L.; Pendergast, A. M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell Biol. 1995, 15, 5531-5541.
40. Pendergast, A. M.; Quilliam, L. A.; Cripe, L. D.; Bassing, C. H.; Dai, Z.; Li, N.; Batzer, A.; Rabun, K. M.; Der, C. J.; Schlessinger, J.; et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 1993, 75, 175-185.
41. Zhang, X.; Subrahmanyam, R.; Wong, R.; Gross, A. W.; Ren, R. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol. Cell Biol. 2001, 21, 840-853.
42. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-501.
43. Skorski, T.; Kanakaraj, P.; Nieborowska-Skorska, M.; Ratajczak, M. Z.; Wen, S. C.; Zon, G.; Gewirtz, A. M.; Perussia, B.; Calabretta, B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995, 86, 726-736.
44. Salomoni, P.; Condorelli, F.; Sweeney, S. M.; Calabretta, B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 2000, 96, 676-684.
45. Trotta, R.; Vignudelli, T.; Candini, O.; Intine, R. V.; Pecorari, L.; Guerzoni, C.; Santilli, G.; Byrom, M. W.; Goldoni, S.; Ford, L. P.; Caligiuri, M. A.; Maraia, R. J.; Perrotti, D.; Calabretta, B. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003, 3, 145-160.
46. Ghaffari, S.; Jagani, Z.; Kitidis, C.; Lodish, H. F.; Khosravi-Far, R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 6523-6528.
47. Mohi, M. G.; Boulton, C.; Gu, T. L.; Sternberg, D. W.; Neuberg, D.; Griffin, J. D.; Gilliland, D. G.; Neel, B. G. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 3130-3135.
48. Raitano, A. B.; Halpern, J. R.; Hambuch, T. M.; Sawyers, C. L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 11746-11750.
49. Dickens, M.; Rogers, J. S.; Cavanagh, J.; Raitano, A.; Xia, Z.; Halpern, J. R.; Greenberg, M. E.; Sawyers, C. L.; Davis, R. J. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 1997, 277, 693-696.
50. Ilaria, R. L., Jr.; Van Etten, R. A. P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 1996, 271, 31704-31710.
51. Carlesso, N.; Frank, D. A.; Griffin, J. D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 1996, 183, 811-820.
52. Hoelbl, A.; Schuster, C.; Kovacic, B.; Zhu, B.; Wickre, M.; Hoelzl, M. A.; Fajmann, S.; Grebien, F.; Warsch, W.; Stengl, G.; Hennighausen, L.; Poli, V.; Beug, H.; Moriggl, R.; Sexl, V. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO molecular medicine 2010, 2, 98-110.
53. Bewry, N. N.; Nair, R. R.; Emmons, M. F.; Boulware, D.; Pinilla-Ibarz, J.; Hazlehurst, L. A. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol. Cancer Ther. 2008, 7, 3169-3175.
54. Wang, Y.; Cai, D.; Brendel, C.; Barett, C.; Erben, P.; Manley, P. W.; Hochhaus, A.; Neubauer, A.; Burchert, A. Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood 2007, 109, 2147-2155.
55. Jiang, X.; Lopez, A.; Holyoake, T.; Eaves, A.; Eaves, C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 12804-12809.
56. Traer, E.; MacKenzie, R.; Snead, J.; Agarwal, A.; Eiring, A. M.; O'Hare, T.; Druker, B. J.; Deininger, M. W. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012, 26, 1140-1143.
57. Nair, R. R.; Tolentino, J. H.; Argilagos, R. F.; Zhang, L.; Pinilla-Ibarz, J.; Hazlehurst, L. A. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leukemia Res. 2012, 36, 756-763.
58. Weisberg, E.; Wright, R. D.; McMillin, D. W.; Mitsiades, C.; Ray, A.; Barrett, R.; Adamia, S.; Stone, R.; Galinsky, I.; Kung, A. L.; Griffin, J. D. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol. Cancer Ther. 2008, 7, 1121-1129.
59. Sattler, M.; Griffin, J. D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin. Hematol. 2003, 40, 4-10.
60. Ren, R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 2005, 5, 172-183.
61. Rosenthal, S.; Canellos, G. P.; Whang-Peng, J.; Gralnick, H. R. Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications. Am. J. Hematol. 1977, 63, 542-547.
62. Calabretta, B.; Perrotti, D. The biology of CML blast crisis. Blood 2004, 103, 4010-4022.
63. Shet, A. S.; Jahagirdar, B. N.; Verfaillie, C. M. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 2002, 16, 1402-1411.
64. Collins, S. J.; Groudine, M. T. Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis. Blood 1987, 69, 893-898.
65. Huntly, B. J.; Bench, A. J.; Delabesse, E.; Reid, A. G.; Li, J.; Scott, M. A.; Campbell, L.; Byrne, J.; Pinto, E.; Brizard, A.; Niedermeiser, D.; Nacheva, E. P.; Guilhot, F.; Deininger, M.; Green, A. R. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002, 99, 4547-4553.
66. Roche-Lestienne, C.; Deluche, L.; Corm, S.; Tigaud, I.; Joha, S.; Philippe, N.; Geffroy, S.; Lai, J. L.; Nicolini, F. E.; Preudhomme, C. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 2008, 111, 3735-3741.
67. Mullighan, C. G.; Williams, R. T.; Downing, J. R.; Sherr, C. J. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes & development 2008, 22, 1411-1415.
68. Mullighan, C. G.; Miller, C. B.; Radtke, I.; Phillips, L. A.; Dalton, J.; Ma, J.; White, D.; Hughes, T. P.; Le Beau, M. M.; Pui, C. H.; Relling, M. V.; Shurtleff, S. A.; Downing, J. R. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008, 453, 110-114.
69. Lanza, F.; Bi, S. Role of p53 in leukemogenesis of chronic myeloid leukemia. Stem Cells 1995, 13, 445-452.
70. Barnes, D. J.; Palaiologou, D.; Panousopoulou, E.; Schultheis, B.; Yong, A. S.; Wong, A.; Pattacini, L.; Goldman, J. M.; Melo, J. V. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res. 2005, 65, 8912-8919.
71. Barnes, D. J.; Schultheis, B.; Adedeji, S.; Melo, J. V. Dosedependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 2005, 24, 6432-6440.
72. Modi, H.; McDonald, T.; Chu, S.; Yee, J. K.; Forman, S. J.; Bhatia, R. Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood 2007, 109, 5411-5421.
73. Skorski, T. Oncogenic tyrosine kinases and the DNA-damage response. Nat. Rev. Cancer 2002, 2, 351-360.
74. Yong, A. S.; Melo, J. V. The impact of gene profiling in chronic myeloid leukaemia. Best Pract. Res. Clin. Hematol. 2009, 22, 181-190.
75. Melo, J. V.; Barnes, D. J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 2007, 7, 441-453.
76. Radich, J. P.; Dai, H.; Mao, M.; Oehler, V.; Schelter, J.; Druker, B.; Sawyers, C.; Shah, N.; Stock, W.; Willman, C. L.; Friend, S.; Linsley, P. S. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 2794-2799.
77. Oehler, V. G.; Guthrie, K. A.; Cummings, C. L.; Sabo, K.; Wood, B. L.; Gooley, T.; Yang, T.; Epping, M. T.; Shou, Y.; Pogosova-Agadjanyan, E.; Ladne, P.; Stirewalt, D. L.; Abkowitz, J. L.; Radich, J. P. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells. Blood 2009, 114, 3299-3308.
78. Neviani, P.; Santhanam, R.; Trotta, R.; Notari, M.; Blaser, B. W.; Liu, S.; Mao, H.; Chang, J. S.; Galietta, A.; Uttam, A.; Roy, D. C.; Valtieri, M.; Bruner-Klisovic, R.; Caligiuri, M. A.; Bloomfield, C. D.; Marcucci, G.; Perrotti, D. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8, 355-368.
79. Koptyra, M.; Cramer, K.; Slupianek, A.; Richardson, C.; Skorski, T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008, 22, 1969-1972.
80. Stoklosa, T.; Poplawski, T.; Koptyra, M.; Nieborowska-Skorska, M.; Basak, G.; Slupianek, A.; Rayevskaya, M.; Seferynska, I.; Herrera, L.; Blasiak, J.; Skorski, T. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 2008, 68, 2576-2580.
81. Chang, J. S.; Santhanam, R.; Trotta, R.; Neviani, P.; Eiring, A. M.; Briercheck, E.; Ronchetti, M.; Roy, D. C.; Calabretta, B.; Caligiuri, M. A.; Perrotti, D. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood 2007, 110, 994-1003.
82. Perrotti, D.; Cesi, V.; Trotta, R.; Guerzoni, C.; Santilli, G.; Campbell, K.; Iervolino, A.; Condorelli, F.; Gambacorti-Passerini, C.; Caligiuri, M. A.; Calabretta, B. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat. Genet. 2002, 30, 48-58.
83. Wagner, K.; Zhang, P.; Rosenbauer, F.; Drescher, B.; Kobayashi, S.; Radomska, H. S.; Kutok, J. L.; Gilliland, D. G.; Krauter, J.; Tenen, D. G. Absence of the transcription factor CCAAT enhancer binding protein alpha results in loss of myeloid identity in bcr/ablinduced malignancy. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 6338-6343.
84. Guo, Z.; Dose, M.; Kovalovsky, D.; Chang, R.; O'Neil, J.; Look, A. T.; von Boehmer, H.; Khazaie, K.; Gounari, F. Beta-catenin stabilization stalls the transition from double-positive to singlepositive stage and predisposes thymocytes to malignant transformation. Blood 2007, 109, 5463-5472.
85. Jamieson, C. H.; Ailles, L. E.; Dylla, S. J.; Muijtjens, M.; Jones, C.; Zehnder, J. L.; Gotlib, J.; Li, K.; Manz, M. G.; Keating, A.; Sawyers, C. L.; Weissman, I. L. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 2004, 351, 657-667.
86. Perrotti, D.; Neviani, P. From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin. Cancer Res. 2007, 13, 1638-1642.
87. Abrahamsson, A. E.; Geron, I.; Gotlib, J.; Dao, K. H.; Barroga, C. F.; Newton, I. G.; Giles, F. J.; Durocher, J.; Creusot, R. S.; Karimi, M.; Jones, C.; Zehnder, J. L.; Keating, A.; Negrin, R. S.; Weissman, I. L.; Jamieson, C. H. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 3925-3929.
88. Klein, F.; Feldhahn, N.; Herzog, S.; Sprangers, M.; Mooster, J. L.; Jumaa, H.; Muschen, M. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006, 25, 1118-1124.
89. Passegue, E.; Wagner, E. F.; Weissman, I. L. JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 2004, 119, 431-443.
90. Hoshino, K.; Quintas-Cardama, A.; Radich, J.; Dai, H.; Yang, H.; Garcia-Manero, G. Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leukemia Res. 2009, 33, 1361-1366.
91. Hromas, R.; Collins, S. J.; Hickstein, D.; Raskind, W.; Deaven, L. L.; O'Hara, P.; Hagen, F. S.; Kaushansky, K. A retinoic acidresponsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J. Biol. Chem. 1991, 266, 14183-14187.
92. Gaboli, M.; Kotsi, P. A.; Gurrieri, C.; Cattoretti, G.; Ronchetti, S.; Cordon-Cardo, C.; Broxmeyer, H. E.; Hromas, R.; Pandolfi, P. P. Mzf1 controls cell proliferation and tumorigenesis. Gene Dev. 2001, 15, 1625-1630.
93. Perrotti, D.; Melotti, P.; Skorski, T.; Casella, I.; Peschle, C.; Calabretta, B. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol. Cell Biol. 1995, 15, 6075-6087.
94. Guaita, S.; Puig, I.; Franci, C.; Garrido, M.; Dominguez, D.; Batlle, E.; Sancho, E.; Dedhar, S.; De Herreros, A. G.; Baulida, J. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J. Biol. Chem. 2002, 277, 39209-39216.
95. Nelson, W. J.; Nusse, R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004, 303, 1483-1487.
96. Cramer, K.; Nieborowska-Skorska, M.; Koptyra, M.; Slupianek, A.; Penserga, E. T.; Eaves, C. J.; Aulitzky, W.; Skorski, T. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 2008, 68: 6884-6888.
97. Brazma, D.; Grace, C.; Howard, J.; Melo, J. V.; Holyoke, T.; Apperley, J. F.; Nacheva, E. P. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression. Genes Chromosomes Canc. 2007, 46, 1039-1050.
98. Radich, J. P. The biology of chronic myelogenous leukemia progression: who, what, where, and why? Hematol. Oncol. Clin. N. 2011, 25, 967-980, v.
99. Deutsch, E.; Dugray, A.; AbdulKarim, B.; Marangoni, E.; Maggiorella, L.; Vaganay, S.; M'Kacher, R.; Rasy, S. D.; Eschwege, F.; Vainchenker, W.; Turhan, A. G.; Bourhis, J. BCRABL down-regulates the DNA repair protein DNA-PKcs. Blood 2001, 97, 2084-2090.
100. Slupianek, A.; Schmutte, C.; Tombline, G.; Nieborowska-Skorska, M.; Hoser, G.; Nowicki, M. O.; Pierce, A. J.; Fishel, R.; Skorski, T. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol. Cell 2001, 8, 795-806.
101. Sattler, M.; Verma, S.; Shrikhande, G.; Byrne, C. H.; Pride, Y. B.; Winkler, T.; Greenfield, E. A.; Salgia, R.; Griffin, J. D. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J. Biol. Chem. 2000, 275, 24273-24278.
102. Eiring, A. M.; Harb, J. G.; Neviani, P.; Garton, C.; Oaks, J. J.; Spizzo, R.; Liu, S.; Schwind, S.; Santhanam, R.; Hickey, C. J.; Becker, H.; Chandler, J. C.; Andino, R.; Cortes, J.; Hokland, P.; Huettner, C. S.; Bhatia, R.; Roy, D. C.; Liebhaber, S. A.; Caligiuri, M. A.; Marcucci, G.; Garzon, R.; Croce, C. M.; Calin, G. A.; Perrotti, D. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010, 140, 652-665.
103. Tenen, D. G.; Hromas, R.; Licht, J. D.; Zhang, D. E. Transcription factors, normal myeloid development, and leukemia. Blood 1997, 90, 489-519.
104. Tenen, D. G. Disruption of differentiation in human cancer: AML shows the way. Nat. Rev. Cancer 2003, 3, 89-101.
105. Gao, S. M.; Yang, J.; Chen, C.; Zhang, S.; Xing, C. Y.; Li, H.; Wu, J.; Jiang, L. miR-15a/16-1 enhances retinoic acid-mediated differentiation of leukemic cells and is up-regulated by retinoic acid. Leukemia Lymphoma 2011, 52, 2365-2371.
106. Bueno, M. J.; Perez de Castro, I.; Gomez de Cedron, M.; Santos, J.; Calin, G. A.; Cigudosa, J. C.; Croce, C. M.; Fernandez-Piqueras, J.; Malumbres, M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13, 496-506.
107. Suresh, S.; McCallum, L.; Lu, W.; Lazar, N.; Perbal, B.; Irvine, A. E. MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML. Cell Commun. Signal. 2011, 5, 183-191.
108. McCallum, L.; Price, S.; Planque, N.; Perbal, B.; Pierce, A.; Whetton, A. D.; Irvine, A. E. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 2006, 108, 1716-1723.
109. Viswanathan, S. R.; Powers, J. T.; Einhorn, W.; Hoshida, Y.; Ng, T. L.; Toffanin, S.; O'Sullivan, M.; Lu, J.; Phillips, L. A.; Lockhart, V. L.; Shah, S. P.; Tanwar, P. S.; Mermel, C. H.; Beroukhim, R.; Azam, M.; Teixeira, J.; Meyerson, M.; Hughes, T. P.; Llovet, J. M.; Radich, J.; Mullighan, C. G.; Golub, T. R.; Sorensen, P. H.; Daley, G. Q. Lin28 promotes transformation and is associated with advanced human malignancies. Nature genetics 2009, 41, 843-848.
110. O'Hare, T.; Zabriskie, M. S.; Eiring, A. M.; Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer 2012, 12, 513-526.
111. Hochhaus, A.; Muller, M. C.; Radich, J.; Branford, S.; Kantarjian, H. M.; Hanfstein, B.; Rousselot, P.; Kim, D. W.; Lipton, J. H.; Bleickardt, E.; Lambert, A.; Hughes, T. P. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009, 23, 1628-1633.
112. Druker, B. J. Circumventing resistance to kinase-inhibitor therapy. New Engl. J. Med. 2006, 354, 2594-2596.
113. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414, 105-111.
114. Peterson, L. F.; Mitrikeska, E.; Giannola, D.; Lui, Y.; Sun, H.; Bixby, D.; Malek, S. N.; Donato, N. J.; Wang, S.; Talpaz, M. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia 2011, 25, 761-769.
115. Wang, J. C.; Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005, 15, 494-501.
116. Graham, S. M.; Jorgensen, H. G.; Allan, E.; Pearson, C.; Alcorn, M. J.; Richmond, L.; Holyoake, T. L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99, 319-325.
117. Copland, M.; Hamilton, A.; Elrick, L. J.; Baird, J. W.; Allan, E. K.; Jordanides, N.; Barow, M.; Mountford, J. C.; Holyoake, T. L. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107, 4532-4539.
118. Michor, F.; Hughes, T. P.; Iwasa, Y.; Branford, S.; Shah, N. P.; Sawyers, C. L.; Nowak, M. A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435, 1267-1270.
119. Hu, Y.; Chen, Y.; Douglas, L.; Li, S. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23, 109-116.
120. Ito, T.; Kwon, H. Y.; Zimdahl, B.; Congdon, K. L.; Blum, J.; Lento, W. E.; Zhao, C.; Lagoo, A.; Gerrard, G.; Foroni, L.; Goldman, J.; Goh, H.; Kim, S. H.; Kim, D. W.; Chuah, C.; Oehler, V. G.; Radich, J. P.; Jordan, C. T.; Reya, T. Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 2010, 466, 765-768.
121. Cosset, E.; Hamdan, G.; Jeanpierre, S.; Voeltzel, T.; Sagorny, K.; Hayette, S.; Mahon, F. X.; Dumontet, C.; Puisieux, A.; Nicolini, F. E.; Maguer-Satta, V. Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia. Blood 2011, 117, 1673-1676.
122. Li, L.; Wang, L.; Wang, Z.; Ho, Y.; McDonald, T.; Holyoake, T. L.; Chen, W.; Bhatia, R. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012, 21, 266-281.
123. Dierks, C.; Beigi, R.; Guo, G. R.; Zirlik, K.; Stegert, M. R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer cell 2008, 14, 238-249.
124. Zhao, C.; Chen, A.; Jamieson, C. H.; Fereshteh, M.; Abrahamsson, A.; Blum, J.; Kwon, H. Y.; Kim, J.; Chute, J. P.; Rizzieri, D.; Munchhof, M.; VanArsdale, T.; Beachy, P. A.; Reya, T. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009, 458, 776-779.
125. Cea, M.; Cagnetta, A.; Cirmena, G.; Garuti, A.; Rocco, I.; Palermo, C.; Pierri, I.; Reverberi, D.; Nencioni, A.; Ballestrero, A.; Gobbi, M.; Carella, A. M.; Patrone, F. Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status. Leukemia Lymphoma 2012, 54, 342-352.
126. Eiring, A. M.; Neviani, P.; Santhanam, R.; Oaks, J. J.; Chang, J. S.; Notari, M.; Willis, W.; Gambacorti-Passerini, C.; Volinia, S.; Marcucci, G.; Caligiuri, M. A.; Leone, G. W.; Perrotti, D. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008, 111, 816-828.
127. Coluccia, A. M.; Vacca, A.; Dunach, M.; Mologni, L.; Redaelli, S.; Bustos, V. H.; Benati, D.; Pinna, L. A.; Gambacorti-Passerini, C. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J. 2007, 26, 1456-1466.
128. Minami, Y.; Stuart, S. A.; Ikawa, T.; Jiang, Y.; Banno, A.; Hunton, I. C.; Young, D. J.; Naoe, T.; Murre, C.; Jamieson, C. H.; Wang, J. Y. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 17967-17972.
129. Zhao, C.; Blum, J.; Chen, A.; Kwon, H. Y.; Jung, S. H.; Cook, J. M.; Lagoo, A.; Reya, T. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12, 528-541.
130. Lim, S.; Saw, T. Y.; Zhang, M.; Janes, M. R.; Nacro, K.; Hill, J.; Lim, A. Q.; Chang, C. T.; Fruman, D. A.; Rizzieri, D. A.; Tan, S. Y.; Fan, H.; Chuah, C. T.; Ong, S. T. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc. Natl. Acad. Sci. U. S. A. 2013, 110, E2298-2307.
131. Samanta, A.; Perazzona, B.; Chakraborty, S.; Sun, X.; Modi, H.; Bhatia, R.; Priebe, W.; Arlinghaus, R. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 2011, 25, 463-472.
132. Arlinghaus, R. B. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia. Oncogene 2002, 21, 8560-8567.
133. Zhang, B.; Ho, Y. W.; Huang, Q.; Maeda, T.; Lin, A.; Lee, S. U.; Hair, A.; Holyoake, T. L.; Huettner, C.; Bhatia, R. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 2012, 21, 577-592.
134. Klionsky, D. J. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol. 2007, 8, 931-937.
135. Levine, B.; Klionsky, D. J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6, 463-477.
136. Levine, B. Cell biology: autophagy and cancer. Nature 2007, 446, 745-747.
137. Efeyan, A.; Sabatini, D. M. mTOR and cancer: many loops in one pathway. Curr. Opin. Cell Biol 2010, 22, 169-176.
138. Rabinowitz, J. D.; White, E. Autophagy and metabolism. Science 2010, 330, 1344-1348.
139. Settembre, C.; Di Malta, C.; Polito, V. A.; Garcia Arencibia, M.; Vetrini, F.; Erdin, S.; Erdin, S. U.; Huynh, T.; Medina, D.; Colella, P.; Sardiello, M.; Rubinsztein, D. C.; Ballabio, A. TFEB links autophagy to lysosomal biogenesis. Science 2011, 332, 1429-1433.
140. Zhao, J.; Brault, J. J.; Schild, A.; Cao, P.; Sandri, M.; Schiaffino, S.; Lecker, S. H.; Goldberg, A. L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab. 2007, 6, 472-483.
141. Ertmer, A.; Huber, V.; Gilch, S.; Yoshimori, T.; Erfle, V.; Duyster, J.; Elsasser, H. P.; Schatzl, H. M. The anticancer drug imatinib induces cellular autophagy. Leukemia 2007, 21, 936-942.
142. Bellodi, C.; Lidonnici, M. R.; Hamilton, A.; Helgason, G. V.; Soliera, A. R.; Ronchetti, M.; Galavotti, S.; Young, K. W.; Selmi, T.; Yacobi, R.; Van Etten, R. A.; Donato, N.; Hunter, A.; Dinsdale, D.; Tirro, E.; Vigneri, P.; Nicotera, P.; Dyer, M. J.; Holyoake, T.; Salomoni, P.; Calabretta, B. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 2009, 119, 1109-1123.
143. Altman, B. J.; Jacobs, S. R.; Mason, E. F.; Michalek, R. D.; MacIntyre, A. N.; Coloff, J. L.; Ilkayeva, O.; Jia, W.; He, Y. W.; Rathmell, J. C. Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis. Oncogene 2011, 30, 1855-1867.
144. Corbin, A. S.; Agarwal, A.; Loriaux, M.; Cortes, J.; Deininger, M. W.; Druker, B. J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 2011, 121, 396-409.
145. Helgason, G. V.; Karvela, M.; Holyoake, T. L. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011, 118, 2035-2043.
146. Carella, A. M.; Beltrami, G.; Pica, G.; Carella, A.; Catania, G. Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leukemia Lymphoma 2012, 53, 1409-1411.